Efficacy of cyclophosphamide in sarcoid radiculomyelitis

Zuber, M; Defer, G; Cesaro, P; Degos, J D
February 1992
Journal of Neurology, Neurosurgery & Psychiatry;Feb1992, Vol. 55 Issue 2, p166
Academic Journal
case study
No abstract available.


Related Articles

  • Treatment of periocular and non-ocular sarcoids in 18 horses by interstitial brachytherapy with iridium-192. Byam-Cook, K. L.; Henson, F. M. D.; Slater, J. D. // Veterinary Record: Journal of the British Veterinary Association;9/9/2006, Vol. 159 Issue 11, p337 

    Treatment of the equine sarcoid has posed a significant challenge to clinicians for years and many different methods have been tried with varying success, including ionising radiation. The aim of this study was to review the efficacy of iridium-192 interstitial brachytherapy for the treatment of...

  • Low-dose methotrexate lowers inflammation in uveitis. Guttman, Cheryl // Ophthalmology Times;03/01/98, Vol. 23 Issue 5, p11 

    Details the efficacy of low-dose methotrexate in treating idiopathic panuveitis and chronic sarcoid. Background of the study regarding the treatment; Side effects of the drug.

  • Meningitis and Radiculomyelitis Caused by Angiostrongylus cantonensis. Maretić, Tomislav; Perović, Marta; Vince, Adriana; Lukas, Davorka; Dekumyoy, Paron; Begovac, Josip // Emerging Infectious Diseases;Jun2009, Vol. 15 Issue 6, p996 

    A letter to the editor about a case of meningitis and radiculomyelitis caused by Angiostrongylus cantonensis is presented.

  • Interstitial brachytherapy of equine sarcoids with iridium-192.  // Veterinary Record: Journal of the British Veterinary Association;9/9/2006, Vol. 159 Issue 11, p332 

    The article cites a study that examines the efficacy of interstitial brachytherapy with iridium-192 for treating sarcoids in horses. In several cases, the lesions were surgically debulked before treatment. After brachytherapy, all the periocular and 13 of the non-ocular sarcoids went into...

  • 318. Cyclophosphamide and prednisone improve membranous nephropathy. Branten, A.J.W.; Wetzels, J.F.M. // Kidney;May/Jun2002, Vol. 11 Issue 3, p104 

    Deals with a study which examined the efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Methodology; Results; Conclusion.

  • Cyclophosphamide.  // Reactions Weekly;6/15/2013, Issue 1457, p16 

    An abstract of the article "Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder," by K. Yaguchi and colleagues is presented.

  • Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p134 

    This meta-analysis of the most recent studies comparing cyclophosphamide with mycophenolate mofetil (MMF) for the treatment of lupus nephritis suggests that MMF offers similar efficacy to cyclophosphamide, with less toxicity.

  • High dose coachable compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Lambert, Hannah E.; Berry, Roger J. // British Medical Journal (Clinical Research Edition);3/23/1985, Vol. 290 Issue 6472, p889 

    Compares the efficacy of cisplatin and cyclophosphamide in the treatment of advanced epithelial ovarian cancer. Increase in the median survival time in patients administered with cisplatin; Significance of the difference in disease free survival; Advantage of cisplatin over cyclophosphamide.

  • Immune agents target inflammation. Foroozan, Rod // Ophthalmology Times;10/1/2009, Vol. 34 Issue 19, p22 

    The article features immune agents for treating inflammatory diseases that involve the eye or orbit. Cyclophosphamide is a nitrogen mustard derivative alkylating agent used to treat patients with idiopathic orbital inflammation. Methotrexate is a potent dihydrofolate reductase inhibitor used to...

  • Clinical pharmacokinetics of cyclophosphamide. de Jonge, Milly E.; Huitema, Alwin D. R.; Rodenhuis, Sjoerd; Beijnen, Jos H. // Clinical Pharmacokinetics;2005, Vol. 44 Issue 11, p1135 

    Cyclophosphamide is an extensively used anticancer and immunosuppressive agent. It is a prodrug undergoing a complicated process of metabolic activation and inactivation. Technical difficulties in the accurate determination of the cyclophosphamide metabolites have long hampered the assessment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics